An observational study in Genetic Disease, sponsored by Illumina, Inc.. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2024-04-30.
Sponsored by Illumina, Inc. · Observational
Prospective observational study to further understand the value that a multi-omic approach has in individuals with a multi system, early onset disorder that does not have a molecular diagnosis by whole genome sequencing.
Understand the value and utilization of integrated multi-omics, in multi-system early onset disorders that have failed to yield findings by whole genome sequencing
403 studies on the registry are indexed under Genetic Diseases, Inborn; 145 are open to participants now.
This study's planned enrollment of 150 is below the median of 192 across 195 observational studies indexed under Genetic Diseases, Inborn.
Browse Genetic Diseases, Inborn studies →Illumina, Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Outpatient setting with eighty percent consisting of prior negative genome cases that have previously received a clinical whole genome sequencing (cWGS) test. Remaining twenty percent will be positive controls who previously have a definitive diagnosis from clinical genetic testing.
Undiagnosed probands must meet all of the following:
Diagnosed probands must meet all of the following:
Exclusion Criteria:
Undiagnosed probands must not meet any:
Diagnosed probands must not meet any:
Based on analysis of data from completed clinical utility evaluation surveys following receipt of study results by the PI, assess whether a patient's change of management resulted from the multi-omic results
Understand the value and utilization of integrated multi-omics, in multi-system early onset disorders that have failed to yield findings by whole genome sequencing
Time frame: 120 Days
Number of diagnoses yielded by each of the different orthogonally confirmed assay results
Assess the number of new diagnoses yielded by each approach
Time frame: 120 Days
Analyze data from completed clinical utility evaluation surveys; number of patients with change of management and whether the change was due to a diagnosis yielded by multiomic results
Analyze the clinical utility derived from a diagnosis
Time frame: 120 Days
Data utilization of multi-omic dataset for scientific community
Establish a multi-omic reference dataset from resource limited populations that can be used by the scientific community
Time frame: 120 Days
This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Illumina, Inc.